Navigation Links
Mymetics Corporation Information to be Available Through Standard & Poor's Market Access Program
Date:8/25/2008

NYON, Switzerland, August 25 /PRNewswire-FirstCall/ -- Mymetics Corporation (OTCBB:MYMX) announced today that its company information will be made available via Standard & Poor's Market Access Program, an information distribution service that enables subscribing publicly traded companies to have their company information disseminated to users of Standard & Poor's Advisor Insight. The company information to be made available through this program includes share price, volume, dividends, shares outstanding, company financial position, and earnings. Standard & Poor's Advisor Insight is an Internet-based research engine used by more than 100,000 investment advisors. A public version of the site is available at http://www.advisorinsight.com.

In addition, information about companies in Standard & Poor's Market Access Program will be available via S&P's Stock Guide database, which is distributed electronically to virtually all major quote vendors. As part of the program, a full description of Mymetics Corporation will also be published in the Daily News section of Standard Corporation Records, a recognized securities manual for secondary trading in approximately 38 states under their Blue Sky Laws.

Company information distributed through the Market Access Program is based upon information that Standard & Poor's considers to be reliable, but neither Standard & Poor's nor its affiliates warrant its completeness or accuracy, and it should not be relied upon as such. This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument.

Mymetics have further contracted with BlueSkyMLS http://www.blueskymls.com to seek registration in states not covered by the S&P Market Access Program.

Ernest Luebke, Chief Financial Officer of Mymetics Corporation stated "We are very pleased with the level of professionalism demonstrated by Standard & Poor's as well as BlueSkyMLS in assisting us with our US exemption process."

About Mymetics Corporation

Mymetics' primary objective is to develop vaccines and therapies to prevent and treat the effects of certain retroviruses and other infectious diseases, including the human immunodeficiency virus, or HIV, the virus that leads to acquired immunodeficiency syndrome, or AIDS. Mymetics has also recently acquired from a close scientific partner an advanced malaria vaccine project currently in phase Ib clinical trial. Additional applications of Mymetics's research include potential treatments and/or vaccines for human oncoviral leukemias, multiple sclerosis, and organ transplantation.

Contacts:

Anthony Jessop

Senior Vice President Mymetics, Inc.

tel: North America +1-303-800-6606

ajessop@mymetics.com

Standard & Poor's Customer Contact:

Richard Albanese

+1-212-438-3647

richard_albanese@sandp.com

Standard and Poor's Media Relations Contact:

Michael Privitera

+1-212-438-6679

michael_privitera@sandp.com

BlueSkyMLS Contact :

Theodore J. Dragon

+1-201-804-3909 x 113

tdragon@blueskymls.com


'/>"/>
SOURCE Mymetics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Mymetics Corporation Important Shareholders Information Conference Call
2. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
3. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
4. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
5. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
6. MannKind Corporation Reports Second Quarter Financial Results
7. Genaera Corporation Announces Second Quarter Financial Results
8. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
9. Pharmos Corporation Reports 2008 Second Quarter Results
10. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
11. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf ... join the faculty of the University of North Carolina Kenan-Flagler Business School ... and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
Breaking Biology Technology:
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
Breaking Biology News(10 mins):